

# The Trendlines Group

## Shareholder update

---

Steve Rhodes  
Chairman and CEO

Todd Dollinger  
Chairman and CEO

Haim Brosh  
Chief Financial Officer

October 2020

# Agenda

---

- Corporate highlights
- Covid-19 impact
- Portfolio company highlights

# Legal disclaimer

---

## Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

# Key corporate developments in 2020

---

- 9<sup>th</sup> Exit - sale of ApiFix Ltd.
- Trendlines Agrifood Fund Pte. Ltd. invested in three companies – Equinom Ltd., Insectta Ltd. and Saturas Ltd.
- Establishment of two new medical portfolio companies – Senter Care Ltd. (Israel) and STeP Pte. Ltd. (Singapore)
- 33 portfolio companies raised >US\$38 million.
- Trendlines Labs, our in-house innovation center, expanded into Singapore and China
- Trendlines expands activities in China with the opening of Trendlines Medical Shanghai Innovation Center

# Portfolio value expansion



# Covid-19 impact

---

- Work practices in all offices altered to ensure safety and health of all
- Budgets and workplans for portfolio companies revised to extend cash runways and account for current environment
- Travel restrictions, lockdowns, and hospital policies have impacted commercial and clinical trial stage companies
- Maximizing efforts to showcase our portfolio companies to investors and update our shareholders via digital platforms

# Our most recent exit – April 2020

Minimally invasive non-fusion surgical system for treating progressive adolescent idiopathic scoliosis

## Achievements

- Sales in Canada, Europe, Israel, Asia, U.S.
- Completed >360 successful surgical procedures
- Offices in Israel and U.S.
- Received FDA, CE mark

- Acquired by  OrthoPediatrics®  
Leading innovation in Pediatric Orthopedics
- Purchase price: US\$67 million + earnout\*
- **Trendlines' return: 37% IRR\***  
**15X ROI\***

\*as at share price on closing date



The Apifix minimally invasive scoliosis treatment system

# ApiFix




**2011** Founded  
**2020** Exited



**Investors** Trendlines,  
B. Braun



# An “inventory” of companies nearing potential exit



\*55 portfolio companies as at 30 June 2020;



# Numerous near-term portfolio performance targets

	2021	2022	2023/24
<b>AgroScout</b>	Rapid sales growth	Add new markets, new crops	
<b>AquiNovo</b>	Regulatory approval	Launch first product with ADM	Launch 2nd product
<b>Arcuro</b>	Expand US sales		
<b>BioFishency</b>	Rapid sales growth	Launch 2nd product	
<b>FruitSpec</b>	Rapid sales growth	Launch additional applications	
<b>liberDi</b>	Regulatory approval, pivotal clinicals		
<b>miRobot</b>	Advanced field trials	Launch commercial sales	
<b>OrthoSpin</b>	2nd regulatory approval, sales		
<b>PregnanTech</b>	Launch pivotal clinical trial		
<b>Phytolon</b>	Pilots with multiple partners	Scale production capabilities	
<b>Saturas</b>	Rapid sales growth		
<b>ProArc</b>	Launch pivotal clinical trial		
<b>Senter Care</b>	Complete field trials	Partnership agreements; launch	International expansion
<b>Sol Chip</b>	Rapid sales growth		
<b>ViAqua</b>	Regulatory approval, scale production	Launch first product with ADM	Expand new product pipeline

# Smart external fixation with real-time feedback

A smart external fixation system that allows real-time physician follow-up and reduces dependency on patient compliance

## Achievements

- Successful FIH in US and Israel
- Received FDA clearance
- Two investments from J&J Innovation



The OrthoSpin strut and control box are part of a smart external fixation system



**Founded** 2014



**CEO** Oren Cohen  
**Chair** Assaf Dekel, MD



**IP** 1 National phase  
(U.S., EU, China); 1  
provisional



**Funding** US\$7.9 million



**Investors**  
Trendlines,  
J&J Innovation



**Our Board Members**  
Todd Dollinger,  
Barak Singer





# Novel system for meniscus repair

An all-suture, knotless meniscus repair system

## Achievements

- Initial sales in the United States
- FDA and CE regulatory approvals
- Distributors in the US; LATAM and APAC countries



The innovative Arcuro system for meniscus repair



**Founded** 2013



**CEO** Lee Ranon



**IP** U.S. and Chinese patents



**Funding** ~US\$6.6 million



**Investors** Strategic and Private investors, surgeons



**Our Board Members**  
Todd Dollinger,  
Barak Singer




# A natural food color revolution

A broad-spectrum of healthy plant-based colors produced via fermentation technology, using baker's yeast as a biofactory. Phytolon's high-quality and cost-effective pigments offer value for consumers, the environment and food industry

## Achievements

- Full POC: color production & food application
- Market focus verified from industry leaders
- Pilots projects at global food industry leaders
- Raised US\$4.6 million, including from strategic investors



Plant-based colors produced via cost-effective and sustainable fermentation of yeast



**Founded** 2018



**CEO** Halim Jubran, PhD



**IP** licensed from Weizmann institute of Science



**Funding** US\$4.6 million



**Investors** Millenium, CBG, Trendlines, Mory Arkin,



**Our Board Members** Maya Schushan Orgad, PhD




# Bringing accuracy to fruit yield estimation


Providing accurate, early-season fruit yield estimations using hyperspectral imaging and AI technology.

## Achievements

- 2019: Commercial sales in the US and South Africa
- 2020: Commercial sales launch Q1 in Chile
- Applicable for citrus and stone fruits, apples, grapes (table and wine) and avocados
- Proven accuracy rate >90% (average, 97%)



The machine vision technology can estimate from an early stage (green fruit)



# FruitSpec.



**Founded** 2016



**CEO** Raviv Kula



**IP** 2 US patents granted, listing process in other territories



**Funding** Raised US\$5 million in investment rounds




**Our Board Members**  
Sarai Kemp, Steve Rhodes



# Looking ahead

---



**Our quality of life depends upon our health and food.**

More than ever, our medical and agrifood investments impact lives and provide significant value creation opportunities.



# Creating and developing companies to improve the human condition

SGX: 42T  
OTCQX: TRNLY

+972.72.260.7000  
[www.trendlines.com](http://www.trendlines.com)



Steve Rhodes, Chairman & CEO

Todd Dollinger, Chairman & CEO

Haim Brosh, Chief Financial Officer

October 2020